1. Home
  2. AIRE vs XCUR Comparison

AIRE vs XCUR Comparison

Compare AIRE & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$1.48

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

XCUR

Exicure Inc.

HOLD

Current Price

$1.70

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRE
XCUR
Founded
2021
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
13.7M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
AIRE
XCUR
Price
$1.48
$1.70
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$1.30
N/A
AVG Volume (30 Days)
44.0K
43.1K
Earning Date
04-28-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
60.34
83.37
EPS
N/A
N/A
Revenue
$4,518,498.00
N/A
Revenue This Year
$129.06
N/A
Revenue Next Year
$83.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
376.42
N/A
52 Week Low
$0.16
$1.43
52 Week High
$3.98
$9.50

Technical Indicators

Market Signals
Indicator
AIRE
XCUR
Relative Strength Index (RSI) 30.96 31.68
Support Level $0.29 N/A
Resistance Level $2.17 $3.40
Average True Range (ATR) 0.16 0.27
MACD -0.06 -0.01
Stochastic Oscillator 0.00 17.77

Price Performance

Historical Comparison
AIRE
XCUR

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: